Castle Biosciences Says Patients With Uveal Melanoma Tested With DecisionDx-UM Report Gaining Value from Test Results In Study Conducted In Collaboration With Melanoma Research Foundation's CURE OM Initiative
Castle Biosciences Says Patients With Uveal Melanoma Tested With DecisionDx-UM Report Gaining Value from Test Results In Study Conducted In Collaboration With Melanoma Research Foundation's CURE OM Initiative
Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced findings from a study that evaluated uveal melanoma (UM) patients' attitudes toward prognostic testing and specifically with respect to DecisionDx-UM®. Highlights from the study were shared in a poster presentation at the 20th congress of the International Society of Ocular Oncology (ISOO), recently held in Leiden, The Netherlands.
通過指導患者護理的創新測試來改善健康的卡塞爾生物科學公司(納斯達克代碼：CSTL)今天宣佈了一項研究的結果，該研究評估了葡萄膜黑色素瘤(UM)患者對預後測試的態度，特別是關於Dx-UM®的態度。這項研究的亮點在最近於荷蘭萊頓舉行的國際眼科腫瘤學會(ISOO)第20屆大會的海報演示中得到了分享。
The poster, titled "Uveal Melanoma Patient Attitudes Towards Prognostic Testing Using Gene Expression Profiling" and presented by Basil K. Williams, Jr., M.D., assistant professor in the Department of Ophthalmology and Mary Knight Asbury Chair of Ocular Oncology at the University of Cincinnati College of Medicine, can be viewed here.
這張海報題為《葡萄膜黑色素瘤患者對使用基因表達譜進行預後檢測的態度》，由辛辛那提大學醫學院眼科助理教授、醫學博士、眼科助理教授瑪麗·奈特·阿斯伯裏提出，可點擊此處查看。
"Most patients impacted by the rare but quite deadly disease, uveal melanoma, want and expect to play an active role in their care to ensure the best possible outcome," said Williams. "We believe the survey data supported this sentiment and found that regardless of their overall prognosis, patients value the information provided by their DecisionDx-UM test results."
威廉姆斯説：“大多數受到葡萄膜黑色素瘤這種罕見但相當致命的疾病影響的患者，都希望並期望在他們的護理中發揮積極作用，以確保最好的結果。”我們認為調查數據支持這一觀點，並發現，無論他們的總體預後如何，患者都重視他們的DecisionDx-UM測試結果提供的信息。
Study highlights:
研究要點：
- An online questionnaire was distributed by the Melanoma Research Foundation's CURE OM (Ocular Melanoma) initiative to capture anonymous information regarding patient-reported experiences following prognostic testing.
- Patients were asked questions regarding the decision to undergo prognostic testing and the extent to which they felt decision regret.
- Of the 177 survey participants, 90% reported wanting prognostic information at diagnosis.
- Of the patients who received prognostic testing with DecisionDx-UM, there was no significant difference in decision regret levels among those receiving a low- (Class 1A), intermediate- (Class 1B) or high-risk (Class 2) test result (Kruskal-Wallis rank sum test, X2=4.1, p=0.13).
- Patients tested with DecisionDx-UM reported gaining value from their test result, including:
- Increased knowledge and understanding of their disease
- More personalized treatment options
- Information relevant to life planning
- Relief from uncertainty about the future
- 黑色素瘤研究基金會的治療OM(眼睛黑色素瘤)倡議分發了一份在線問卷，以獲取關於患者在預後測試後報告的經歷的匿名信息。
- 患者被問到關於接受預後測試的決定以及他們對決定後悔的程度的問題。
- 在177名調查參與者中，90%的人報告在診斷時希望得到預後信息。
- 在接受Dx-UM預後測試的患者中，接受低(1A類)、中(1B類)或高風險(2類)測試結果的患者在決定後悔水平上沒有顯著差異(Kruskal-Wallis秩和檢驗，X2=4.1，p=0.13)。
- 接受DecisionDx-UM測試的患者報告從他們的測試結果中獲得了價值，包括：
- 增加對他們的疾病的知識和了解
- 更個性化的治療選擇
- 與人生規劃相關的信息
- 從未來的不確定性中解脱出來
譯文內容由第三人軟體翻譯。